Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

400 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Gaspar N, Janeway K, Campbell-Hewson Q, Lawlor ER, Copland C, Karres D, Norga K, Benzaghou F, Weiner S, Weigel B, Weiss AR, Strauss SJ, Smith M, Setty BA, Seibel N, Scobie N, Pappo A, Okpara CE, Nysom K, McDonough J, Marshall LV, Ludwinski D, Ligas F, Lesa G, Knudsen S, Kauh J, Hsieh A, Heenen D, Hawkins DS, Graham A, Garmey E, DuBois SG, Fox E, Donoghue M, de Rojas T, Chung J, Casanova M, Brennan B, Bishop M, Buenger V, Reaman G, Vassal G. Pearson AD, et al. Eur J Cancer. 2022 Sep;173:71-90. doi: 10.1016/j.ejca.2022.06.008. Epub 2022 Jul 18. Eur J Cancer. 2022. PMID: 35863108 Free article. Review.
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.
Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C. Bax DA, et al. Among authors: pearson ad. PLoS One. 2009;4(4):e5209. doi: 10.1371/journal.pone.0005209. Epub 2009 Apr 14. PLoS One. 2009. PMID: 19365568 Free PMC article.
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C. Bax DA, et al. Among authors: pearson ad. Clin Cancer Res. 2009 Sep 15;15(18):5753-61. doi: 10.1158/1078-0432.CCR-08-3210. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737945
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis RM, Hargrave D, Workman P, Jones C. Gaspar N, et al. Among authors: pearson ad. Cancer Res. 2010 Nov 15;70(22):9243-52. doi: 10.1158/0008-5472.CAN-10-1250. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935218 Free PMC article.
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project.
Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Moroz V, et al. Among authors: pearson ad. Eur J Cancer. 2011 Mar;47(4):561-71. doi: 10.1016/j.ejca.2010.10.022. Epub 2010 Nov 26. Eur J Cancer. 2011. PMID: 21112770
Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience.
Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Morgenstern DA, et al. Among authors: pearson ad. J Pediatr Hematol Oncol. 2014 Apr;36(3):218-23. doi: 10.1097/MPH.0000000000000003. J Pediatr Hematol Oncol. 2014. PMID: 24322496
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, Griffin MJ, Yule M, Hargrave D. Moreno L, et al. Among authors: pearson ad. Clin Cancer Res. 2015 Jan 15;21(2):267-73. doi: 10.1158/1078-0432.CCR-14-1592. Epub 2014 Nov 4. Clin Cancer Res. 2015. PMID: 25370467 Clinical Trial.
400 results